Novocure Ltd Company Profile (NASDAQ:NVCR)

About Novocure Ltd (NASDAQ:NVCR)

Novocure Ltd logoNovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NVCR
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.02 billion
  • Outstanding Shares: 88,149,000
Average Prices:
  • 50 Day Moving Avg: $11.32
  • 200 Day Moving Avg: $8.64
  • 52 Week Range: $5.95 - $14.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -41.43
  • P/E Growth: -0.24
Sales & Book Value:
  • Annual Revenue: $104.71 million
  • Price / Sales: 9.77
  • Book Value: $1.46 per share
  • Price / Book: 7.95
  • EBIDTA: ($84,840,000.00)
  • Net Margins: -219.29%
  • Return on Equity: -69.89%
  • Return on Assets: -50.57%
  • Debt-to-Equity Ratio: 0.61%
  • Current Ratio: 9.14%
  • Quick Ratio: 8.33%
  • Average Volume: 944,826 shs.
  • Beta: 4.17
  • Short Ratio: 14.91

Frequently Asked Questions for Novocure Ltd (NASDAQ:NVCR)

What is Novocure Ltd's stock symbol?

Novocure Ltd trades on the NASDAQ under the ticker symbol "NVCR."

How were Novocure Ltd's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) posted its quarterly earnings data on Thursday, April, 27th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.04. The firm had revenue of $34.88 million for the quarter, compared to the consensus estimate of $39.46 million. Novocure Ltd had a negative return on equity of 69.89% and a negative net margin of 219.29%. View Novocure Ltd's Earnings History.

Where is Novocure Ltd's stock going? Where will Novocure Ltd's stock price be in 2017?

7 analysts have issued 1 year target prices for Novocure Ltd's shares. Their forecasts range from $9.00 to $34.00. On average, they anticipate Novocure Ltd's share price to reach $17.00 in the next twelve months. View Analyst Ratings for Novocure Ltd.

What are analysts saying about Novocure Ltd stock?

Here are some recent quotes from research analysts about Novocure Ltd stock:

  • 1. According to Zacks Investment Research, "NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. " (5/3/2017)
  • 2. JPMorgan Chase & Co. analysts commented, "NVCR’s 1Q report (slides here) was largely uneventful as the co continues to make progress with the Optune launch. 1Q net revenues were $35M vs. consensus of $41M (though we note the cash vs. accrual accounting makes net revenue hard to predict). There were 1,266 active patients on therapy at 1Q-end (+16% q/q), ahead of our 1,226 estimate. We are encouraged by the progress here, though will be looking for momentum to continue to build following recent reimbursement wins, NCCN guidelines, as well as impressive follow-up survival data from the pivotal EF-14 trial." (5/1/2017)

Are investors shorting Novocure Ltd?

Novocure Ltd saw a increase in short interest in April. As of April 28th, there was short interest totalling 7,558,939 shares, an increase of 7.9% from the April 13th total of 7,002,815 shares. Based on an average daily trading volume, of 624,192 shares, the short-interest ratio is presently 12.1 days.

Who are some of Novocure Ltd's key competitors?

Who owns Novocure Ltd stock?

Novocure Ltd's stock is owned by a variety of of institutional and retail investors. Top institutional investors include DOYLE WILLIAM F (22.70%), POMONA CAPITAL VII, L.P. (11.30%), PERLHAGEN GERT L. (6.90%), FMR LLC (5.20%), Vanguard Group Inc. (3.46%) and VOLATI LTD (2.20%). Company insiders that own Novocure Ltd stock include Asaf Danziger, Gert L Perlhagen, Michael J Ambrogi, Robert J Mylod Jr and Yoram Palti. View Institutional Ownership Trends for Novocure Ltd.

Who sold Novocure Ltd stock? Who is selling Novocure Ltd stock?

Novocure Ltd's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Nationwide Fund Advisors, Courage Capital Management LLC, Goldman Sachs Group Inc., Credit Suisse AG, Hartline Investment Corp and ProShare Advisors LLC. Company insiders that have sold Novocure Ltd stock in the last year include Gert L Perlhagen, Michael J Ambrogi and Yoram Palti. View Insider Buying and Selling for Novocure Ltd.

Who bought Novocure Ltd stock? Who is buying Novocure Ltd stock?

Novocure Ltd's stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., River & Mercantile Asset Management LLP, Peregrine Capital Management LLC, Wedbush Securities Inc., Geode Capital Management LLC, Bank of America Corp DE, Creative Planning and Teachers Advisors LLC. Company insiders that have bought Novocure Ltd stock in the last two years include Asaf Danziger, Gert L Perlhagen and Robert J Mylod Jr. View Insider Buying and Selling for Novocure Ltd.

How do I buy Novocure Ltd stock?

Shares of Novocure Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Novocure Ltd stock cost?

One share of Novocure Ltd stock can currently be purchased for approximately $11.60.

Analyst Ratings

Consensus Ratings for Novocure Ltd (NASDAQ:NVCR) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $17.00 (46.55% upside)

Analysts' Ratings History for Novocure Ltd (NASDAQ:NVCR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/1/2017JPMorgan Chase & Co.Reiterated RatingBuy$14.00HighView Rating Details
4/28/2017Deutsche Bank AGBoost Price TargetHold$10.00 -> $11.00LowView Rating Details
4/27/2017WedbushReiterated RatingOutperform$20.00LowView Rating Details
4/18/2017AegisReiterated RatingBuy$14.00LowView Rating Details
4/4/2017JMP SecuritiesReiterated RatingOutperform$34.00HighView Rating Details
1/11/2017Wells Fargo & CoDowngradeOutperform -> Market PerformN/AView Rating Details
7/29/2016Barclays PLCLower Price TargetUnderweight$12.00 -> $9.00N/AView Rating Details
11/12/2015Evercore ISIInitiated CoverageBuy$29.00N/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for Novocure Ltd (NASDAQ:NVCR)
Earnings by Quarter for Novocure Ltd (NASDAQ:NVCR)
Earnings History by Quarter for Novocure Ltd (NASDAQ:NVCR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/20173/31/2017($0.25)($0.21)$39.46 million$34.88 millionViewN/AView Earnings Details
2/23/2017Q416($0.39)($0.26)$26.95 million$30.20 millionViewN/AView Earnings Details
11/2/2016Q3 2016($0.42)($0.39)$21.65 million$21.67 millionViewN/AView Earnings Details
7/28/2016Q216($0.37)($0.48)$15.90 million$17.90 millionViewListenView Earnings Details
5/9/2016Q116($0.33)($0.42)$23.65 million$13.10 millionViewN/AView Earnings Details
10/26/2015Q315($2.09)$4.37 million$8.95 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Novocure Ltd (NASDAQ:NVCR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.26)($0.26)($0.26)
Q3 20171($0.25)($0.25)($0.25)
Q4 20171($0.25)($0.25)($0.25)
(Data provided by Zacks Investment Research)


Dividend History for Novocure Ltd (NASDAQ:NVCR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Novocure Ltd (NASDAQ:NVCR)
Insider Ownership Percentage: 33.90%
Institutional Ownership Percentage: 21.98%
Insider Trades by Quarter for Novocure Ltd (NASDAQ:NVCR)
Institutional Ownership by Quarter for Novocure Ltd (NASDAQ:NVCR)
Insider Trades by Quarter for Novocure Ltd (NASDAQ:NVCR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/19/2017Yoram PaltiInsiderSell8,000$11.39$91,120.00View SEC Filing  
5/17/2017Yoram PaltiInsiderSell4,000$11.47$45,880.00View SEC Filing  
5/16/2017Yoram PaltiInsiderSell8,000$12.05$96,400.00View SEC Filing  
5/12/2017Yoram PaltiInsiderSell8,000$11.79$94,320.00View SEC Filing  
5/10/2017Yoram PaltiInsiderSell8,000$12.29$98,320.00View SEC Filing  
5/8/2017Yoram PaltiInsiderSell8,000$11.82$94,560.00View SEC Filing  
5/4/2017Yoram PaltiInsiderSell8,000$11.42$91,360.00View SEC Filing  
5/2/2017Yoram PaltiInsiderSell8,000$11.64$93,120.00View SEC Filing  
4/28/2017Yoram PaltiInsiderSell8,000$11.25$90,000.00View SEC Filing  
4/26/2017Yoram PaltiInsiderSell8,000$10.78$86,240.00View SEC Filing  
4/24/2017Yoram PaltiInsiderSell8,000$11.26$90,080.00View SEC Filing  
4/20/2017Yoram PaltiInsiderSell8,000$11.24$89,920.00View SEC Filing  
4/18/2017Yoram PaltiInsiderSell16,000$10.64$170,240.00View SEC Filing  
4/17/2017Yoram PaltiCTOSell4,000$10.77$43,080.00View SEC Filing  
4/13/2017Yoram PaltiCTOSell4,000$10.43$41,720.00View SEC Filing  
4/12/2017Yoram PaltiCTOSell4,000$10.72$42,880.00View SEC Filing  
3/14/2017Gert L PerlhagenDirectorBuy125,000$6.93$866,250.00View SEC Filing  
12/22/2016Michael J AmbrogiCOOSell27,500$8.27$227,425.00View SEC Filing  
12/20/2016Michael J AmbrogiCOOSell20,000$8.62$172,400.00View SEC Filing  
12/19/2016Michael J AmbrogiCOOSell20,000$8.76$175,200.00View SEC Filing  
12/16/2016Michael J AmbrogiCOOSell40,000$8.93$357,200.00View SEC Filing  
12/14/2016Michael J AmbrogiCOOSell40,000$8.97$358,800.00View SEC Filing  
12/12/2016Michael J AmbrogiCOOSell15,000$9.01$135,150.00View SEC Filing  
12/8/2016Michael J AmbrogiCOOSell10,000$8.30$83,000.00View SEC Filing  
12/6/2016Michael J AmbrogiCOOSell10,000$8.24$82,400.00View SEC Filing  
8/5/2016Gert L PerlhagenDirectorSell676,576$1.85$1,251,665.60View SEC Filing  
6/8/2016Michael J AmbrogiCOOSell20,000$12.24$244,800.00View SEC Filing  
3/3/2016Asaf DanzigerCEOBuy10,000$15.00$150,000.00View SEC Filing  
3/3/2016Robert J Mylod JrDirectorBuy20,000$15.78$315,600.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Novocure Ltd (NASDAQ:NVCR)
Latest Headlines for Novocure Ltd (NASDAQ:NVCR)
DateHeadline logoYoram Palti Sells 8,000 Shares of Novocure Ltd (NVCR) Stock - May 22 at 8:15 PM logoNovocure Ltd (NVCR) Short Interest Update - May 22 at 4:14 PM logoNovocure Ltd (NVCR) Insider Sells $45,880.00 in Stock - May 18 at 8:33 PM logoInsider Selling: Novocure Ltd (NVCR) Insider Sells 8,000 Shares of Stock - May 17 at 8:11 PM logoNovocure Ltd (NVCR) Insider Sells $94,320.00 in Stock - May 15 at 7:51 PM logoNovocure™ Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma - May 15 at 10:06 AM logoMartin J. Madden Joins Novocure Board of Directors - May 11 at 9:17 AM logoCombination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Delayed Decline in Several Health-Related Quality of Life Scales Compared to Temozolomide Alone for Newly Diagnosed Glioblastoma Patients - May 8 at 12:16 PM logoNovocure Ltd (NVCR) Expected to Announce Quarterly Sales of $42.2 Million - May 6 at 7:38 AM logoNovocure (NVCR) Receiving Somewhat Favorable News Coverage, Report Finds - May 5 at 10:35 PM logo-$0.21 EPS Expected for Novocure Ltd (NVCR) This Quarter - May 4 at 11:40 PM logoNovocure™ Announces Opening of Two Pilot Trials to Evaluate the Use of TTFields for Pediatric Gliomas - May 4 at 7:01 PM logoNovocure Ltd (NVCR) Receives Average Rating of "Hold" from Analysts - May 3 at 8:38 AM logoZacks Investment Research Lowers Novocure Ltd (NVCR) to Hold - May 3 at 7:50 AM logoNovocure Ltd (NVCR) Insider Sells $90,000.00 in Stock - May 1 at 10:18 PM logoETFs with exposure to Novocure Ltd. : May 1, 2017 - May 1 at 5:52 PM logoETFs with exposure to Novocure Ltd. : May 1, 2017 - May 1 at 5:52 PM logoNovocure™ Announces Data Presentations at the World Federation of Neuro-oncology Societies 5th Quadrennial Meeting - May 1 at 12:12 PM logoNovocure to Present at Three Upcoming Investor Conferences in May - May 1 at 12:12 PM logoJPMorgan Chase & Co. Reiterates Buy Rating for Novocure Ltd (NVCR) - May 1 at 9:30 AM logoQ2 2017 Earnings Forecast for Novocure Ltd (NVCR) Issued By Wedbush - May 1 at 7:54 AM logoNovocure (NVCR) Receives Daily Media Sentiment Score of 0.40 - April 29 at 6:33 PM logoNovocure Ltd (NVCR) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS - April 29 at 1:27 AM logoNovocure Ltd (NVCR) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS - April 29 at 1:25 AM logoNovocure Ltd (NVCR) Announces Quarterly Earnings Results - April 29 at 1:25 AM logoNovocure Ltd (NVCR) Rating Reiterated by Deutsche Bank AG - April 29 at 1:02 AM logoNovocure Ltd. :NVCR-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017 - April 28 at 7:56 PM logoEdited Transcript of NVCR earnings conference call or presentation 27-Apr-17 12:00pm GMT - April 28 at 12:26 AM logoNovocure Ltd (NVCR) Insider Sells $86,240.00 in Stock - April 27 at 9:46 PM logoWedbush Reiterates Ourperform Rating for Novocure Ltd (NVCR) - April 27 at 5:31 PM logoNovocure Reports First Quarter 2017 Financial Results and Provides Company Update - April 27 at 10:11 AM logoNovoCure reports 1Q loss - April 27 at 10:11 AM logoNovocure (NVCR) Earning Somewhat Critical Media Coverage, Study Shows - April 26 at 2:58 PM logoNovocure Ltd (NVCR) Stock Rating Reaffirmed by Aegis - April 24 at 1:10 PM logoNovocure (NVCR) Earns Daily Media Sentiment Rating of 0.11 - April 23 at 8:09 PM logoNovocure Ltd (NVCR) Upgraded by Zacks Investment Research to Buy - April 23 at 5:39 PM logoNovocure Ltd (NVCR) Downgraded by Zacks Investment Research - April 22 at 11:36 AM logoNovocure Ltd (NVCR) Insider Yoram Palti Sells 8,000 Shares - April 21 at 9:06 PM logoNovocure (NVCR) Earns News Impact Score of 0.12 - April 21 at 12:33 AM logoNovocure Ltd (NVCR) CTO Sells $41,720.00 in Stock - April 19 at 11:03 PM logoYoram Palti Sells 4,000 Shares of Novocure Ltd (NVCR) Stock - April 19 at 11:03 PM logoNovocure Ltd (NVCR) CTO Yoram Palti Sells 4,000 Shares - April 19 at 11:03 PM logoNovocure Ltd (NVCR) Insider Yoram Palti Sells 16,000 Shares - April 19 at 8:23 PM logoNovocure™ Announces Four Presentations on Tumor Treating Fields at the American Academy of Neurology Annual Meeting in Boston - April 19 at 10:11 AM logoCommit To Buy NovoCure At $7.50, Earn 11.4% Annualized Using Options - - April 18 at 6:16 PM logoAegis Capital Reiterates Buy Rating and $14 PT on Novocure (NVCR); 'Data from Post-Hoc Analysis Incrementally ... - - April 18 at 6:16 PM logoNovocure Ltd (NVCR) Receives Buy Rating from Aegis - April 18 at 2:04 PM logoNovocure (NVCR) Given Daily News Sentiment Score of 0.15 - April 17 at 4:24 PM logoCNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line Chemotherapies after Glioblastoma Recurrence - April 17 at 9:50 AM logoNovocure says drug shows better survival rates for cancer patients in late-stage trial - April 17 at 9:50 AM



Novocure Ltd (NVCR) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff